Patients and transplant characteristics (n = 1000)
| Variables . | Total (n = 1000) . | Children (n = 846) . | Adults (n = 154) . |
|---|---|---|---|
| Follow-up, months, median (range) | 54.5 (0.3-324.6) | 56.4 (0.3-324.6) | 48.0 (2.18-305.9) |
| Age, years, median (range) | 9.4 (0.26-54.37) | 8.3 (0.3-16.0) | 19.3 (16.0-54.4) |
| Year of transplantation, median (range) | 2007 (1986-2013) | 2007 (1986-2013) | 2008 (1989-2013) |
| Sex, n (%) | |||
| Male | 498 (49.8) | 416 (49.2) | 82 (53.2) |
| Female | 502 (50.2) | 430 (50.8) | 72 (46.8) |
| Source of HSC, n (%) | |||
| BM | 839 (83.9) | 728 (86.1) | 111 (72.1) |
| PBSC | 73 (7.3) | 30 (3.5) | 43 (27.9) |
| CB | 88 (8.8) | 88 (10.4) | — |
| GVHD prophylaxis, n (%) | |||
| CsA | 188 (19.9) | 168 (21.1) | 20 (13.5) |
| CsA+MTX | 533 (56.5) | 470 (59.1) | 63 (42.6) |
| CsA+MMF | 73 (7.7) | 54 (6.8) | 19 (12.8) |
| FK506±other | 110 (11.7) | 89 (11.2) | 21 (14.2) |
| Other | 39 (4.1) | 14 (1.5) | 25 (16.9) |
| In vivo TCD, n (%) | |||
| None | 173 (17.7) | 161 (20.8) | 12 (9.1) |
| ATG | 692 (70.6) | 605 (78.1) | 87 (65.9) |
| OKT3 | 2 (0.2) | 1 (0.1) | 1 (0.8) |
| Campath | 113 (11.5) | 8 (1.0) | 32 (24.2) |
| Conditioning, n (%) | |||
| MAC | 873 (87.4) | 760 (89.8) | 113 (73.4) |
| Bu+Cy | 721 (82.6) | 660 (86.8) | 61 (54.0) |
| Bu+Flu±other | 79 (9.0) | 57 (7.5) | 22 (19.5) |
| Flu±other | 33 (3.8) | 27 (3.6) | 6 (5.3) |
| TBI±other | 26 (3.0) | 6 (0.8) | 20 (17.7) |
| Other or missing | 14 (1.6) | 10 (1.3) | 4 (3.5) |
| RIC | 125 (12.5) | 85 (10.0) | 40 (26.0) |
| Bu+Cy | 3 (2.4) | 2 (2.4) | 1 (2.5) |
| Bu+Flu±other | 22 (17.6) | 14 (16.5) | 8 (20.0) |
| Flu±other | 62 (49.6) | 45 (52.9) | 17 (42.5) |
| TBI±other | 20 (16.0) | 8 (9.4) | 12 (30.0) |
| Other or missing | 18 (14.4) | 16 (18.8) | 2 (5.0) |
| Variables . | Total (n = 1000) . | Children (n = 846) . | Adults (n = 154) . |
|---|---|---|---|
| Follow-up, months, median (range) | 54.5 (0.3-324.6) | 56.4 (0.3-324.6) | 48.0 (2.18-305.9) |
| Age, years, median (range) | 9.4 (0.26-54.37) | 8.3 (0.3-16.0) | 19.3 (16.0-54.4) |
| Year of transplantation, median (range) | 2007 (1986-2013) | 2007 (1986-2013) | 2008 (1989-2013) |
| Sex, n (%) | |||
| Male | 498 (49.8) | 416 (49.2) | 82 (53.2) |
| Female | 502 (50.2) | 430 (50.8) | 72 (46.8) |
| Source of HSC, n (%) | |||
| BM | 839 (83.9) | 728 (86.1) | 111 (72.1) |
| PBSC | 73 (7.3) | 30 (3.5) | 43 (27.9) |
| CB | 88 (8.8) | 88 (10.4) | — |
| GVHD prophylaxis, n (%) | |||
| CsA | 188 (19.9) | 168 (21.1) | 20 (13.5) |
| CsA+MTX | 533 (56.5) | 470 (59.1) | 63 (42.6) |
| CsA+MMF | 73 (7.7) | 54 (6.8) | 19 (12.8) |
| FK506±other | 110 (11.7) | 89 (11.2) | 21 (14.2) |
| Other | 39 (4.1) | 14 (1.5) | 25 (16.9) |
| In vivo TCD, n (%) | |||
| None | 173 (17.7) | 161 (20.8) | 12 (9.1) |
| ATG | 692 (70.6) | 605 (78.1) | 87 (65.9) |
| OKT3 | 2 (0.2) | 1 (0.1) | 1 (0.8) |
| Campath | 113 (11.5) | 8 (1.0) | 32 (24.2) |
| Conditioning, n (%) | |||
| MAC | 873 (87.4) | 760 (89.8) | 113 (73.4) |
| Bu+Cy | 721 (82.6) | 660 (86.8) | 61 (54.0) |
| Bu+Flu±other | 79 (9.0) | 57 (7.5) | 22 (19.5) |
| Flu±other | 33 (3.8) | 27 (3.6) | 6 (5.3) |
| TBI±other | 26 (3.0) | 6 (0.8) | 20 (17.7) |
| Other or missing | 14 (1.6) | 10 (1.3) | 4 (3.5) |
| RIC | 125 (12.5) | 85 (10.0) | 40 (26.0) |
| Bu+Cy | 3 (2.4) | 2 (2.4) | 1 (2.5) |
| Bu+Flu±other | 22 (17.6) | 14 (16.5) | 8 (20.0) |
| Flu±other | 62 (49.6) | 45 (52.9) | 17 (42.5) |
| TBI±other | 20 (16.0) | 8 (9.4) | 12 (30.0) |
| Other or missing | 18 (14.4) | 16 (18.8) | 2 (5.0) |
Missing data: in vivo TCD = 20 patients; conditioning (RIC/MAC) = 2 patients.
ATG, anti-thymocyte globulin; Bu, busulfan; CsA, cyclosporin A; Cy, cyclophosphamide; FK506, tacrolimus; MMF, mycophenolate mofetil; MTX, methotrexate; OKT3, mouse monoclonal anti-CD3 antibody; PBSC, PB stem cell; TCD, T-cell depletion.